Musto, Pellegrino http://orcid.org/0000-0003-3277-6594
Simeon, Vittorio
Cascavilla, Nicola
Falcone, Antonietta
Petrucci, Maria Teresa
Cesini, Laura
Di Raimondo, Francesco
Conticello, Concetta
Ria, Roberto
Catalano, Lucio
Salvatore, Dalila
Mastrullo, Lucia
Gagliardi, Alfredo
Villani, Oreste
Pietrantuono, Giuseppe
D’Arena, Giovanni
Mansueto, Giovanna
Bringhen, Sara
Genuardi, Mariella
Di Renzo, Nicola
Reddiconto, Giovanni
Fragasso, Alberto
Caravita, Tommaso
Scapicchio, Daniele
Marziano, Gioacchino
Boccadoro, Mario
Mangiacavalli, Silvia
Corso, Alessandro
Funding for this research was provided by:
Janssen-Cilag Italy (CEUR 20150012500)
Italian Ministry of Health (RRC-2016-2361129)
Article History
Received: 16 April 2018
Accepted: 14 October 2018
First Online: 23 October 2018
Compliance with ethical standards
: After Local Ethic Committee approval, charts of 134 MM eligible patients treated in 12 Italian centers from January 2002 to May 2015 were reviewed. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Due to the restrospective, observational nature of the study and according to current Italian law, obligatory informed consent was not necessary from all patients for being included in the study. Bortezomib-based treatments were performed according to current clinical practice at local institutions.
: Regarding possible COI with the present paper, PM has participated to Advisory Boards of and has received honoraria from Celgene, Janssen-Cilag, BMS, Amgen, and Takeda; MTP is a member of the Advisory Board and has received honoraria from Celgene, Janssen-Cilag, BMS, Amgen, and Takeda; RR is a member of the Advisory Board of Janssen-Cilag, Consultant for CSL Behring and Speakers bureau for Janssen-Cilag, Celgene, Italfarmaco, BMS, Amgen, and CSL Behring; TC is a member of the Advisory board of Janssen-Cilag, Celgene, BMS, Amgen, and Takeda and received research funds from Celgene; SB is a member of the Advisory Board of Janssen-Cilag, Amgen, and Takeda and received honoraria from Janssen and Cilag, Celgene, Amgen, and BMS; MB is a member of the Advisory Board and has received honoraria from Celgene, Janssen-Cilag, BMS, Amgen, and Takeda. Other authors did not declare any COI.